Evidence map›Paper›PMID 24618719›Full record

ArticlePLoS biology2014

RAS transformation requires CUX1-dependent repair of oxidative DNA damage.

Zubaidah M Ramdzan, Charles Vadnais, Ranjana Pal, Guillaume Vandal, Chantal Cadieux, Lam Leduy, Sayeh Davoudi, Laura Hulea, Lu Yao, Anthony N Karnezis and 3 more

Open access · goldAbstract read
In one paragraph

Article in PLoS biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 63 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Zubaidah M RamdzanGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada.
Charles VadnaisGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada; Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Ranjana PalGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada.
Guillaume VandalGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada; Department of Biology, McGill University, Montreal, Quebec, Canada.
Chantal CadieuxGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada; Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Lam LeduyGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada.
Sayeh DavoudiGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada; Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Laura HuleaGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada; Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Lu YaoGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada; Department of Biochemistry, McGill University, Montreal, Quebec, Canada.
Anthony N KarnezisBC Cancer Agency, Centre for Translational and Applied Genomics, Vancouver, British Columbia, Canada.
Marilène PaquetDépartement de Pathologie et Microbiologie, Faculté de Médecine Vétérinaire, Université de Montréal, St-Hyacinthe, Quebec, Canada.
David DankortGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada; Department of Biology, McGill University, Montreal, Quebec, Canada.
Alain NepveuGoodman Cancer Centre, McGill University, Montreal, Quebec, Canada; Department of Biochemistry, McGill University, Montreal, Quebec, Canada; Department of Medicine, McGill University, Montreal, Quebec, Canada; Department of Oncology McGill University, Montreal, Quebec, Canada.
McGill University Health Centre · CAMcGill University · CABC Cancer Agency · CAUniversité de Montréal · CA

Funding

Canadian Institutes of Health Research MOP-97925Canadian Institutes of Health Research MOP-98010
6 · The paper itself

Abstract

The Cut homeobox 1 (CUX1) gene is a target of loss-of-heterozygosity in many cancers, yet elevated CUX1 expression is frequently observed and is associated with shorter disease-free survival. The dual role of CUX1 in cancer is illustrated by the fact that most cell lines with CUX1 LOH display amplification of the remaining allele, suggesting that decreased CUX1 expression facilitates tumor development while increased CUX1 expression is needed in tumorigenic cells. Indeed, CUX1 was found in a genome-wide RNAi screen to identify synthetic lethal interactions with oncogenic RAS. Here we show that CUX1 functions in base excision repair as an ancillary factor for the 8-oxoG-DNA glycosylase, OGG1. Single cell gel electrophoresis (comet assay) reveals that Cux1⁺/⁻ MEFs are haploinsufficient for the repair of oxidative DNA damage, whereas elevated CUX1 levels accelerate DNA repair. In vitro base excision repair assays with purified components demonstrate that CUX1 directly stimulates OGG1's enzymatic activity. Elevated reactive oxygen species (ROS) levels in cells with sustained RAS pathway activation can cause cellular senescence. We show that elevated expression of either CUX1 or OGG1 prevents RAS-induced senescence in primary cells, and that CUX1 knockdown is synthetic lethal with oncogenic RAS in human cancer cells. Elevated CUX1 expression in a transgenic mouse model enables the emergence of mammary tumors with spontaneous activating Kras mutations. We confirmed cooperation between Kras(G12V) and CUX1 in a lung tumor model. Cancer cells can overcome the antiproliferative effects of excessive DNA damage by inactivating a DNA damage response pathway such as ATM or p53 signaling. Our findings reveal an alternate mechanism to allow sustained proliferation in RAS-transformed cells through increased DNA base excision repair capability. The heightened dependency of RAS-transformed cells on base excision repair may provide a therapeutic window that could be exploited with drugs that specifically target this pathway.

Indexed as

DNA DamageAnimalsCell Line, TumorCells, CulturedCell Transformation, NeoplasticCellular SenescenceDNA RepairGenes, rasHomeodomain ProteinsHumansMammary Neoplasms, ExperimentalMice, TransgenicNuclear ProteinsOxidative StressRepressor ProteinsTranscription FactorsCUX1 protein, humanCux1 protein, mouseHomeodomain ProteinsNuclear ProteinsRepressor ProteinsTranscription Factors

Identifiers

PMID24618719
PMCPMC3949673
OpenAlexW1978236080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.